All In Biotech

Drug Trial Radar · NCT03603106

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions

Assessment of Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Lesions

Last checked: Nov 20, 2026Latest source record: May 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

142

Actual

Start

Nov 25, 2013

Primary completion

Apr 17, 2015

Study completion Apr 17, 2015

Sponsor

Lead sponsor
GuerbetIndustry
Sponsor type
Industry
First posted
Jul 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study was to evaluate the safety (clinical and biological) and pharmacokinetics (plasma and urine) profile of P03277 following single administration at ascending dose levels in healthy subjects.

Conditions

  • Healthy Volunteers
  • Brain Lesion

Interventions

  • P03277Drug

    Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s. Part II: P03277 was administered intravenously with a flow rate of 2 mL/s.

  • PlaceboDrug

    Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s. Part II: Placebo was administered intravenously with a flow rate of 2 mL/s.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic (PK) Parameter CmaxTime frame: From baseline (30 minutes before injection) to 24 hours post-injection
  2. PK Parameter T1/2Time frame: From baseline (30 minutes before injection) to 24 hours post-injection
  3. PK Parameter ClTime frame: From baseline (30 minutes before injection) to 24 hours post-injection
  4. PK Parameter VdTime frame: From baseline (30 minutes before injection) to 24 hours post-injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Pharmacology unit, SGS Life Science Services

    Antwerp, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.